Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTION: Rivaroxaban vs SoC for VTE in LLR
NCT06873321Phase 4Recruiting
- Sponsor
- Science Valley Research Institute
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Science Valley Research Institute. Primary endpoints: Incidence of Venous Thromboembolism at 30 days and Primary Safety Outcome at 30 days. Started Feb 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06873321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873321.